What Has Been the Growth of the Entyvio Market So Far?
The entyvio market has seen considerable growth due to a variety of factors.
• In recent times, the Entyvio market has experienced a CAGR of XX%.
Predictions indicate that its growth will escalate from $XX million in 2024 to $XX million in 2025, maintaining a compound annual growth rate (CAGR) of XX%.
The past growth rate can be linked to a rise in reported inflammatory bowel disease cases, heightened awareness of biologic treatments, an expansion in the utilization of Vedolizumab, a leaning towards gut-selective therapy, and a surge in healthcare spending.
What Are the Future Growth Projections for the Entyvio Template Market?
The entyvio market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for Entyvio is projected to grow at a rate of XX (FCAGR) over the coming years, with an estimate to reach $XX million by 2029, presenting a compound annual growth rate (CAGR) of XX%.
This projected growth within the forecast period can be linked to factors such as the approval of subcutaneous formulations, increased use of maintenance therapy, positive clinical guidelines, minimal systemic immunosuppression, and supportive insurance and reimbursement policies. Key trends set to influence this forecast period will be advances in pipeline and technology, product innovation, strategic partnerships, and increased investments.
What Are the Critical Driver Fuelling The Entyvio Market's Growth?
The growth of the entyvio market is expected to be propelled by the increasing prevalence of inflammatory bowel disease (IBD). This condition is a collection of chronic, recurring inflammatory disorders affecting the gastrointestinal (GI) tract, which stems from an imbalance in the immune system, leading to long-term inflammation and tissue damage. This rising prevalence is attributed to a mix of genetic predisposition, environmental factors like diet and urban lifestyle, increased stress levels, and changes in gut microbes due to factors like the use of antibiotics and lower exposure to natural bacteria. Entyvio functions effectively in treating IBD by targeting and blocking the alpha4beta7 integrin, thus reducing the influx of inflammatory cells to the affected area. This was confirmed in June 2024, when the Centre for Disease Control and Prevention, a US non-profit organization, estimated that the figures for IBD in the United States ranged from 2.4 to 3.1 million individuals. This growing prevalence of IBD is, therefore, fueling the growth of the entyvio market. As for the growth of the entyvio market, it is likely to be further propelled by the continued increase in healthcare expenditure. This refers to the total financial resources spent on health services and commodities to maintain or improve both individual and public health. This increase is attributed to elements like the rising prevalence of chronic diseases, advancements in medical technology, an aging populace requiring more robust care, increased costs of prescription drugs and specialized treatments, and wider access to healthcare services in developed and emerging regions. This healthcare expenditure benefits entyvio by ensuring accessibility to advanced biological therapies for patients with inflammatory bowel diseases like Crohn's disease and ulcerative colitis. It also secures funding for its research, development, distribution, and incorporation into treatment protocols, ultimately boosting patient outcomes and healthcare system efficiency. For instance, a report published by the UK-based Office for National Statistics in May 2023 showed that between 2022 and 2023, UK healthcare spending increased by 5.6%, as opposed to the 0.9% growth of 2022. In 2023, the healthcare expenditure in the UK was around $317.63 billion (£292 billion). This rising healthcare expenditure, therefore, is also driving the growth of the entyvio market.
What Are The Major Segments Within The Global Entyvio Market?
The entyvio market covered in this report is segmented –
1) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion
2) By Treatment Line: First-Line Therapy, Second-Line Therapy
3) By Indication: Ulcerative Colitis (UC), Crohn's Disease (CD)
4) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
Pre-Book The Entyvio Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Entyvio Market?
An influential trend in the entyvio market centers on the creation of maintenance therapies aimed at enhancing the prolonged control of inflammatory bowel disease (IBD). Maintenance therapies denote continuous treatments developed to manage chronic diseases, hinder progression, and support a healthy, stable or improved condition post-achieving the initial therapeutic objectives. The goal of these therapies is to mitigate the chances of recurrences, complications or symptoms with time, thus ensuring long-term management of the disease while enhancing life quality for patients. For instance, Takeda pharmaceutical, a US pharmaceutical company, earned approval in April 2024 from the Food and Drug Administration, the US-based federal agency for the subcutaneous (SC) administration as maintenance therapy for moderately to extremely active Crohn’s disease (CD) in adults following the induction therapy with intravenous (IV) Entyvio. The introduction of the subcutaneous approach permits self-administration via a pre-filled pen, which makes it more user-friendly for patients to manage their treatment at home following an early IV infusion during the induction stage. It has been observed through clinical studies that symptoms significantly improve and remission is induced in Crohn's disease patients treated with Entyvio, compared to placebos.
Who Are the Key Players In The Entyvio Market?
Major companies operating in the entyvio market include:
• Takeda Pharmaceutical Company Limited
What Is The Most Dominant Region In The Entyvio Market?
North America was the largest region in the Entyvio market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the entyvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
